Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$168.54
-0.8%
$180.23
$163.33
$251.99
$48.32B0.251.99 million shs2.84 million shs
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$101.36
-0.4%
$101.62
$71.88
$107.17
$149.97B0.686.59 million shs5.19 million shs
DexCom, Inc. stock logo
DXCM
DexCom
$81.01
-1.0%
$79.80
$57.52
$117.27
$31.76B1.464.35 million shs4.74 million shs
ResMed Inc. stock logo
RMD
ResMed
$250.87
+0.3%
$239.91
$179.42
$263.05
$36.79B0.781.01 million shs635,899 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
-0.87%-2.37%-4.81%-27.34%-27.90%
Boston Scientific Corporation stock logo
BSX
Boston Scientific
-0.35%+2.00%-4.92%-0.18%+32.78%
DexCom, Inc. stock logo
DXCM
DexCom
-1.00%-2.39%-6.84%+7.86%-30.55%
ResMed Inc. stock logo
RMD
ResMed
+0.29%-0.12%-0.82%+13.45%+18.19%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
4.9626 of 5 stars
4.24.03.34.03.62.51.3
Boston Scientific Corporation stock logo
BSX
Boston Scientific
4.6015 of 5 stars
3.63.00.04.23.42.51.3
DexCom, Inc. stock logo
DXCM
DexCom
4.8358 of 5 stars
3.55.00.04.72.82.51.9
ResMed Inc. stock logo
RMD
ResMed
4.1146 of 5 stars
2.31.03.34.62.51.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
2.36
Hold$219.2230.07% Upside
Boston Scientific Corporation stock logo
BSX
Boston Scientific
3.13
Buy$116.0914.53% Upside
DexCom, Inc. stock logo
DXCM
DexCom
2.95
Moderate Buy$98.5021.59% Upside
ResMed Inc. stock logo
RMD
ResMed
2.60
Moderate Buy$259.333.37% Upside

Current Analyst Ratings Breakdown

Latest DXCM, RMD, BSX, and BDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/16/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/16/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$118.00
6/16/2025
DexCom, Inc. stock logo
DXCM
DexCom
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$102.00
6/3/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$261.00 ➝ $241.00
5/30/2025
DexCom, Inc. stock logo
DXCM
DexCom
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$104.00
5/28/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$115.00
5/22/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$217.00 ➝ $185.00
5/22/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$119.00 ➝ $125.00
5/22/2025
DexCom, Inc. stock logo
DXCM
DexCom
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$82.00 ➝ $102.00
5/20/2025
ResMed Inc. stock logo
RMD
ResMed
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOverweight ➝ Overweight$286.00
5/16/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$120.00 ➝ $125.00
(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$20.18B2.39$21.12 per share7.98$89.57 per share1.88
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$16.75B8.95$3.65 per share27.77$14.93 per share6.79
DexCom, Inc. stock logo
DXCM
DexCom
$4.03B7.88$2.25 per share36.04$5.38 per share15.06
ResMed Inc. stock logo
RMD
ResMed
$4.69B7.85$9.23 per share27.19$33.11 per share7.58
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$1.71B$5.2432.1610.781.277.28%15.99%7.36%8/7/2025 (Estimated)
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$1.85B$1.3773.9931.382.6211.58%18.67%10.38%7/23/2025 (Estimated)
DexCom, Inc. stock logo
DXCM
DexCom
$576.20M$1.3460.4632.931.7312.90%30.05%10.00%7/24/2025 (Estimated)
ResMed Inc. stock logo
RMD
ResMed
$1.02B$8.9128.1624.221.7326.15%25.67%18.59%7/30/2025 (Estimated)

Latest DXCM, RMD, BSX, and BDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025Q2 2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$3.28$3.35+$0.07$1.06$5.35 billion$5.27 billion
5/1/2025Q1 2025
DexCom, Inc. stock logo
DXCM
DexCom
$0.33$0.32-$0.01$0.27$1.02 billion$1.04 billion
4/23/2025Q1 2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$0.67$0.75+$0.08$0.45$4.57 billion$4.66 billion
4/23/2025Q3 2025
ResMed Inc. stock logo
RMD
ResMed
$2.36$2.37+$0.01$2.48$1.28 billion$1.29 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$4.162.47%N/A79.39%53 Years
Boston Scientific Corporation stock logo
BSX
Boston Scientific
N/AN/AN/AN/AN/A
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
ResMed Inc. stock logo
RMD
ResMed
$2.120.85%N/A23.79%13 Years

Latest DXCM, RMD, BSX, and BDX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
quarterly$1.042.02%6/9/20256/9/20256/30/2025
4/24/2025
ResMed Inc. stock logo
RMD
ResMed
quarterly$0.530.9%5/8/20255/8/20256/12/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.70
1.13
0.64
Boston Scientific Corporation stock logo
BSX
Boston Scientific
0.47
1.45
0.88
DexCom, Inc. stock logo
DXCM
DexCom
0.55
1.50
1.32
ResMed Inc. stock logo
RMD
ResMed
0.12
3.41
2.49

Institutional Ownership

CompanyInstitutional Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
86.97%
Boston Scientific Corporation stock logo
BSX
Boston Scientific
89.07%
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
ResMed Inc. stock logo
RMD
ResMed
54.98%

Insider Ownership

CompanyInsider Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.36%
Boston Scientific Corporation stock logo
BSX
Boston Scientific
0.50%
DexCom, Inc. stock logo
DXCM
DexCom
0.32%
ResMed Inc. stock logo
RMD
ResMed
0.71%
CompanyEmployeesShares OutstandingFree FloatOptionable
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
74,000286.61 million285.58 millionOptionable
Boston Scientific Corporation stock logo
BSX
Boston Scientific
53,0001.48 billion1.47 billionOptionable
DexCom, Inc. stock logo
DXCM
DexCom
10,300392.11 million390.85 millionOptionable
ResMed Inc. stock logo
RMD
ResMed
9,980146.63 million145.59 millionOptionable

Recent News About These Companies

Analysts Set ResMed Inc. (NYSE:RMD) PT at $259.33
ResMed: A Sleeping Giant Hiding In Plain Sight
3 Cash-Heavy Stocks with Competitive Advantages

New MarketBeat Followers Over Time

Media Sentiment Over Time

Becton, Dickinson and Company stock logo

Becton, Dickinson and Company NYSE:BDX

$168.54 -1.40 (-0.83%)
Closing price 06/18/2025 03:59 PM Eastern
Extended Trading
$170.59 +2.06 (+1.22%)
As of 06/18/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Boston Scientific stock logo

Boston Scientific NYSE:BSX

$101.36 -0.37 (-0.36%)
Closing price 06/18/2025 03:59 PM Eastern
Extended Trading
$101.52 +0.16 (+0.15%)
As of 06/18/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

DexCom stock logo

DexCom NASDAQ:DXCM

$81.01 -0.82 (-1.00%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$81.42 +0.41 (+0.50%)
As of 06/18/2025 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

ResMed stock logo

ResMed NYSE:RMD

$250.87 +0.78 (+0.31%)
Closing price 06/18/2025 03:59 PM Eastern
Extended Trading
$247.85 -3.02 (-1.21%)
As of 06/18/2025 05:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.